Rixa Health Tirzepatide Review

Rixa Health is a telehealth weight-loss clinic offering compounded GLP-1 medications with a consultation-first model and no published prices. Our research (August 7, 2026) found a service with some sensible structural choices—bundled pricing, required follow-ups, no long-term contract—and one finding serious enough to shape the entire review.

The Retatrutide Problem

On the pages we retrieved on August 7, 2026, Rixa Health's site named six substances: semaglutide, tirzepatide, retatrutide, sildenafil, tadalafil and PT-141. Retatrutide appeared as a section heading—"Rixa Health's Functional Telemedicine: Retatrutide"—and we found no FDA-approval or investigational-status disclaimer anywhere on that page. Here is what retatrutide actually is. It is an investigational triple-agonist drug developed by Eli Lilly, currently in Phase 3 trials including the TRIUMPH programme. It is not approved by the FDA for any use. Lilly announced on July 23, 2026 that it intends to submit a Biologics License Application in the first quarter of 2027; if that filing is made and review runs its normal ten-to-twelve-month course, approval would not come before late 2027 or 2028. Critically for a compounding-based telehealth service: retatrutide is not on the FDA's list of bulk drug substances that may be used in compounding under section 503A. That is the specific legal reason compounding pharmacies cannot lawfully make it. Outside a clinical trial, it cannot be legally prescribed, purchased or compounded. We are reporting what the company's own website displayed on the date we checked. We cannot say what Rixa actually dispenses to any individual patient, and it is possible the page is aspirational, out of date, or refers to something we could not see. But a weight-loss telehealth site advertising retatrutide without any statement of its investigational status is a serious thing, and it is the reason this review carries the rating it does.

The Shortage Justification No Longer Applies

Rixa's materials describe offering compounded forms because of "high demand and national shortages." That reasoning is out of date. The tirzepatide shortage was declared resolved in October 2024 and semaglutide in early 2025. With no shortage on the books, 503A pharmacies can no longer rely on one to justify compounding copies of these drugs; lawful patient-specific compounding now turns on a documented clinical reason for the individual patient—a dose not commercially available, an excipient sensitivity, a specific titration need. A provider still citing shortages in 2026 is describing a regulatory world that ended eighteen months ago.

What the Service Actually Offers

Setting the above aside, the operational model is reasonable. Intake is a form, followed by a provider visit reviewing history and goals, then a treatment plan. Monthly follow-ups are required for the first six months—more clinical contact than several cheaper competitors require, and a genuine positive. Medication is described as filled by licensed US pharmacies with fast shipping. There are no contracts or long-term commitments, though a late-cancellation or no-show fee applies.

No Published Pricing

Rixa does not publish prices. Its stated approach is: "During your visit, we'll discuss medication pricing, and you'll only be charged once you approve the plan and cost." Medication and membership are described as bundled with no hidden fees. That is defensible—prices genuinely vary by medication and dose—but it means you cannot compare Rixa against competitors before committing time to a consultation, and you should not assume it is competitive. Ask for the full monthly cost, in writing, before approving anything.

Availability

Rixa reports serving 47 states, with Alaska, Arkansas, Hawaii, North Dakota and South Dakota listed as coming soon.